
Opinion|Videos|October 10, 2024
ESMO 2024: Key Updates From NICHE-2
Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5


































